rintega
-
E
Celldex?s lead program RINTEGA demonstrates overall survival benefit in patients with recurrent glio
Celldex?s lead program RINTEGA demonstrates overall survival benefit in patients with recurrent glioblastoma Celldex Therapeutics, Inc. today presented positive results from the Company?s randomized, double?blind Phase 2 study of RINTEGA (rindopepimut) in patients with EGFRvIII?positive...- EGBOT
- Thread
- celldex patients program recurrent rintega
- Replies: 0
- Forum: News